Alzheimer's - Dementia, Author Interviews, Case Western / 25.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71888" align="alignleft" width="150"]Andrew A. Pieper M.D., Ph.D.Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center Dr. Pieper[/caption] Andrew A. Pieper M.D., Ph.D. Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center   MedicalResearch.com: What is the background for this study? Response: NAD+, a central cellular energy and signaling molecule, declines with age throughout the body, including the brain. When NAD+ falls below necessary levels, cells lose their ability to carry out essential maintenance and survival functions. We found that the NAD+ decline is more severe in brains from people with Alzheimer’s disease (AD) and in mouse models of AD, whereas brains of people with AD pathology but preserved cognition show gene-expression patterns consistent with maintained NAD+ homeostasis.
Author Interviews, Cancer Research / 17.12.2025

[caption id="attachment_71812" align="alignleft" width="200"]Dr. Magdalena Zak PhD in Molecular BioscienceResearch Associate , Research Associate Instructor of Medicine, The Ear Institute University College London Dr. Zak[/caption] MedicalResearch.com Interview with: Magdalena M. Żak, PhD Zangi Lab Instructor | Cardiovascular Research Institute Instructor | Genetics & Genomic Sciences Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine New York, NY 10029 MedicalResearch.com: What is the background for this study? Response: mRNA has proven to be a groundbreaking technology through COVID-19 vaccines, and most mRNA-based therapeutics in development today are still focused on vaccines. However, in principle, mRNA could be used for many diseases in which expression of a therapeutic protein would be beneficial. A major reason mRNA is less commonly used outside of vaccines is the lack of robust targeting: for vaccination, broad expression can be acceptable because the goal is antigen production for immune recognition, but for other applications - especially cancer - targeted delivery and minimized off-target expression are critical to reduce side effects.  Current targeting strategies largely rely on lipid nanoparticles (LNPs), which act as lipid “carriers” for systemic delivery. Although LNPs can be designed to show some tissue tropism, this is often limited to organs such as the liver, spleen, and lungs.
Author Interviews, Cancer Research, Genetic Research / 15.04.2025

MedicalResearch.com Interview with: [caption id="attachment_67937" align="alignleft" width="150"]Myvizhi Esai Selvan, PhDInstructor of Genetics and Genomics Icahn School of Medicine at Mount Sinai Dr. Myvizhi Esai Selvan[/caption] Myvizhi Esai Selvan, PhD Instructor of Genetics and Genomics [caption id="attachment_67961" align="alignleft" width="130"]Zeynep H. Gümüş Dr. Zeynep Gümüş[/caption] Zeynep H. Gümüş, PhD Associate Professor Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: The germline genome of each individual person has a unique combination of millions of genetic variants that influence virtually all biological processes throughout life, including cancer evolution. In this study, we have investigated the impact of germline variants – genetic defects one is born with – on gene expression and protein abundance in tumors across cancer types. MedicalResearch.com: Would you describe the technique of precision peptidomics? Response: We have leveraged a cohort of 1,064 patients with multiple cancer types to explore the impact of germline variations on cancer-relevant genes through multiple-omics layers: from DNA to RNA, protein abundance and post-translational modifications. To assess the effects of coding variants and their association with cognate proteins, we used precision peptidomics, which is the quantification of peptides carrying genetic variants from individual patients. Through this approach, we mapped 337,469 protein coding germline variants onto patient peptides, revealing their potential impact on protein modifications, protein stability, allele-specific expression, and protein structure by leveraging the relevant protein databases.
Alzheimer's - Dementia, Author Interviews / 02.05.2024

MedicalResearch.com Interview with: [caption id="attachment_61640" align="alignleft" width="110"]Dr. Li Gan PhDBurton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases Brain and Mind Research Institute Weill Cornell Medical College Dr. Li Gan[/caption] Dr. Li Gan PhD Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases Brain and Mind Research Institute Weill Cornell Medical College [caption id="attachment_61627" align="alignleft" width="150"]Shiaoching Gong PhD Helen and Robert Appel Alzheimer’s Disease Institute Feil Family Brain and Mind Research Institute Weill Cornell Medicine, New York, NY Dr. Shiaoching Gong[/caption] Shiaoching Gong PhD Helen and Robert Appel Alzheimer’s Disease Institute Feil Family Brain and Mind Research Institute Weill Cornell Medicine, New York, NY MedicalResearch.com: What is the background for this study? Would you describe the process of making these neurons? Response: Primary tauopathies are a group of progressive neurodegenerative diseases characterized by the pathological aggregation of 3R or 4R tau protein in neurons and/or glial cells, where 4R tauopathies are more common primary tauopathies. The exact pathological mechanisms remain elusive. There are currently no therapies available that can halt or reverse the spread of tau aggregates since the drug effects found in animal models are not always reproduced in human clinical trials. The development of tau therapies from human cells have become urgently needed. Induced human pluripotent stem cells (iPSCs) offer a unique model to better understand pathological mechanisms underlying human diseases and to develop human cell-based therapy. However, a major challenge to study 4R tauopathy is iPSC-derived neurons express very low levels of 4R Tau isoforms making it difficult to study 4R tauopathy and the mutations located in 4R Tau. To address this need, we designed and engineered a robust human iPSC 4R tauopathy model using CRISPR/Cas9 technology. We first introduced specific mutations at the intron-exon 10 junctions and silent mutations within exon 10 to promote exon 10 inclusion, leading the increase of 4R isoforms expression in iPSC-derived neurons. Frontotemporal Dementia (FTD) mutation, P301S located in exon 10 is highly aggregation prone. To generate this human disease 4R tauopathy model, we then introduced this mutation to 4R iPSC to make it a 4RP301S iPSC line.
Author Interviews, Brigham & Women's - Harvard, Gastrointestinal Disease, Obstructive Sleep Apnea, Technology / 18.11.2023

MedicalResearch.com Interview with: [caption id="attachment_61077" align="alignleft" width="150"]Giovanni Traverso MD PhDKarl Van Tassel (1925) Career Development Professor Department of Mechanical Engineering Koch Institute of Integrative Cancer Research Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA Dr. Traverso[/caption] Giovanni Traverso MD PhD Karl Van Tassel (1925) Career Development Professor Department of Mechanical Engineering Koch Institute of Integrative Cancer Research Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA   MedicalResearch.com: What is the background for this study? Response: I think its always important to acknowledge that this is a big team effort.  We have the teams from MIT, Celero Systems, West Virgnia University (WVU) and Brigham and Women’s Hospital (BWH) all working together on this.   For this study, Celero prototyped the devices that we tested in pre-clinical (Swine) models and in a first-in-human study with the team at WVU. Our lab focuses on the development of ingestible devices for drug delivery and sensing and these have informed the development of these efforts as you can see. MedicalResearch.com: What types of vital signs are measurable in this fashion? Response: Heart rate and respiratory rate.
Alzheimer's - Dementia, Author Interviews, Baylor College of Medicine Houston / 22.10.2023

MedicalResearch.com Interview with: [caption id="attachment_60949" align="alignleft" width="200"]David B. Corry, M.D.Professor of Pathology & Immunology and Medicine Vice Chair for Immunology Department of Pathology & Immunology Biology of Inflammation Center Dan L. Duncan Comprehensive Cancer Center   Clarence and Irene H. Fulbright Chair in Pathology Baylor College of Medicine Michael E. Debakey VA Medical Center Dr. Corry[/caption] David B. Corry, M.D. Professor of Pathology & Immunology and Medicine Vice Chair for Immunology Department of Pathology & Immunology Biology of Inflammation Center Dan L. Duncan Comprehensive Cancer Center   Clarence and Irene H. Fulbright Chair in Pathology Baylor College of Medicine Michael E. Debakey VA Medical Center MedicalResearch.com: What is the background for this study? Can candida species cross the blood brain barrier? Response: We showed earlier (2019) that the common fungus Candida albicans can enter the brain from the blood. That earlier study was in turn inspired by the finding of another research group that had found Candida in the brains of persons suffering from Alzheimer’s Disease and related dementing illnesses.
Author Interviews, Brigham & Women's - Harvard, Neurology, Pain Research / 29.03.2022

MedicalResearch.com Interview with: [caption id="attachment_58952" align="alignleft" width="200"]William R. Renthal, MD, PhD Director of Research, John R. Graham Headache Center Department of Neurology Brigham and Women's Hospital Assistant Professor of Neurology, Harvard Medical School Dr. Renthal[/caption] William R. Renthal, MD, PhD Director of Research, John R. Graham Headache Center Department of Neurology Brigham and Women's Hospital Assistant Professor of Neurology, Harvard Medical School MedicalResearch.com:  What is the background for this study?  Response: We know that a nervous system structure called the trigeminal ganglion plays a critical role in migraine headache, but the cell types that exist in this structure are poorly understood. We have used cutting-edge, single-cell genomic technologies to profile the genes expressed within each trigeminal ganglion cell type in both human and mouse with the goal of identifying molecular features that could allow us to inhibit head pain selectively without affecting other cell types.